

Special Issue

Glucose Metabolism in Cardiovascular Diseases

Message from the Guest Editors

The Special Issue will explore various topics relating to glucose metabolism and its implications for cardiovascular health. These topics include the longstanding issues historically associated with cardiovascular disease risk factors, the relationship between statin medications affecting mitochondrial function and potentially leading to glucose metabolism, and the potential of glucose intolerance to contribute to heart failure. Additionally, the issue will delve into the effects of MRA, beta-blockers, SGLT-2 inhibitors, and ARNI medications on glucose metabolism and cardiovascular outcomes. Lastly, this Special Issue will discuss the integration of IoT technologies for improving the management of cardiovascular health and glucose metabolism, offering insights into innovative approaches for real-time monitoring and personalized interventions. By addressing these topics comprehensively, the Special Issue can provide valuable insights into the complex interplay between glucose metabolism, cardiovascular disease, and therapeutic interventions, thus offering new perspectives and strategies for optimizing patient outcomes.

Guest Editors

Dr. Hidenori Komiyama

Department of Cardiology, Saitama Medical Center, Saitama Medical University, Saitama 350-8550, Japan

Prof. Dr. Kuniya Asai

Department of Cardiovascular Medicine, Nippon Medical School Hospital, Nippon Medical School, Tokyo 113-8603, Japan

Deadline for manuscript submissions

closed (31 March 2025)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/200364

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).